We understand that businesses within life science face a rapidly evolving landscape with frequently changing regulatory requirements and a range of emerging risks.

INDUSTRY

Life Sciences

Managing risk to protect your innovations

Contact us

Flexible approach, local knowledge, and a global reach

We understand that businesses within life science face a rapidly evolving landscape with frequently changing regulatory requirements and a range of emerging risks.

We have an intense focus on client service and a real passion to challenge and explore every aspect of risk associated with your business. This gives you the assurance of having a program that is tailored to your unique requirements.

In a changing insurance market, as specialists, we challenge our clients with fresh thinking and work with them to develop quality risk profiles to present to underwriters for optimum outcomes.

Being the world’s largest privately-owned insurance broker, our clients benefit from the strong relationships Lockton has built with domestic and international providers.

Our own Global Healthcare Network, gives us powerful leverage within the marketplace to successfully deliver cost-effective, bespoke insurance programs for each client’s individual requirements; without jeopardising coverage.

A creative and expanding range of solutions

We understand that the life sciences industry is different and a customised program is crucial in protecting businesses involved in pharmaceutical, research and development, medical device manufacturing, and human clinical trials. When it comes to managing risk it’s the quality of our thinking and our proactive approach that makes us different.

We also recognise the executive risk challenges faced by boards across the spectrum of life sciences and pharmaceutical companies, particularly those listed on the ASX. Whether it be renewal of your D&O liability insurance, coverage for a forthcoming initial public offering or new capital raising, we will work closely with you to ensure your program reflects your own risk appetite at a competitive premium.

Lockton is a member of AusBiotech, the leading Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy.

Products and Services

By understanding what you do and what your individual needs are, we ensure there are no coverage gaps or overlaps within your insurance program including:

  • Life Science Insurance 

  • Clinical Trials Insurance, along with the ability to deliver quick issuance of certification

  • Product Liability

  • Property and Business Interruption, including supply chain risk

  • Professional Indemnity 

  • Directors & Officers

  • Cyber

  • Other specialised life sciences services, such as:

    • product recall;

    • medical malpractice;

    • supply chain risk review;

    • marine cargo;

    • employee benefits; and

    • additional industry solutions.

An industry-leading team of experts focused on the unique risks facing the life sciences industry.

Key Contacts

Placeholder image

Robert Giardina

Manager - Global Professional & Financial Risks
robert.giardina@lockton.com
+61 455 129 332

Questions? We'll guide you in the right direction.

Ask us about our products, services or anything else on your mind. Our insurance and risk specialists are here to help.

Contact us

Latest from Lockton

As the foundational infrastructure for today’s digital economy, data centers pose exacting standards to stakeholders at each phase of development. From design to operation: embedding resilience across the data center lifecycle

Australia’s new digital asset licensing regime: what it means and why insurance matters.

Australia’s new digital asset licensing regime: what it means and why insurance mattersAustralia’s new digital asset licensing regime: what it means and why insurance matters

Lockton Secures Reinsurance Licence in Saudi Arabia Appoints Mohammed Al Rowais as CEO for Reinsurance

Lockton Secures Reinsurance Licence in Saudi Arabia 

Appoints Mohammed Al Rowais as CEO for Reinsurance Lockton Secures Reinsurance Licence in Saudi Arabia 

Appoints Mohammed Al Rowais as CEO for Reinsurance

Directors Duties: lessons from ASIC v Bekier [2026] FCA 196

The Federal Court’s decision in ASIC v Bekier & Ors [2026] FCA 196 is a significant reminder for directors and officers of the elements of their duty of care under s180(1) of the Corporations Act 2001 (Cth) (Corporations Act). It provides a useful illustration of the roles and responsibilities between management and non-executive directors and the factors that will be considered by the Courts when determining liability. The proceeding was brought by ASIC against 11 past directors and officers of The Star Entertainment Group Limited (Star). 
The Federal Court’s decision in ASIC v Bekier & Ors [2026] FCA 196 is a significant reminder for directors and officers of the elements of their duty of care under s180(1) of the Corporations Act 2001 (Cth) (Corporations Act). It provides a useful illustration of the roles and responsibilities between management and non-executive directors and the factors that will be considered by the Courts when determining liability. The proceeding was brought by ASIC against 11 past directors and officers of The Star Entertainment Group Limited (Star).
See all news and insights

With a global footprint of 150+ offices and partner offices, find one near you.

Find an office
global communication network concept